Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Roche to Acquire Arius for C$191 Million
August 4, 2008
- 61.4% of People Favor Use of Consumption Tax for Social Security Services
August 4, 2008
- Roche to Completely Acquire Genentech
August 4, 2008
- R&D NEWS IN BRIEF
July 28, 2008
- Vildagliptin More Effective than Voglibose
July 28, 2008
- REGULATORY NEWS IN BRIEF －２－
July 28, 2008
- REGULATORY NEWS IN BRIEF －１－
July 28, 2008
- Korosho Requires Makers of MTX to Take New Measures to Prevent Overdosing
July 28, 2008
- BUSINESS NEWS IN BRIEF
July 28, 2008
- Korosho Shows Interest in GPOs of the US
July 28, 2008
- JPLA SEMINAR
July 28, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 28, 2008
- Average Wage Hike \5,949 in 2008
July 28, 2008
- Gefitinib Beneficial for Adenocarcinoma Regardless of Smoking History
July 28, 2008
- Pfizer to Develop Market for Sutent as First-Line Therapy for RCC
July 28, 2008
- Clopidogrel May Be Less Effective in Japanese than in Westerners
July 28, 2008
- Eisai Develops Add'l Indications, Dosage Forms for Aricept as Part of Life Cycle Management
July 28, 2008
- Korosho Presents Draft Vision for Medical Devices Industry
July 28, 2008
- Kyowa Hakko, Lonza Extend Their Strategic Collaboration
July 28, 2008
- Asahi Kasei to Enter Market for Advanced Medical Devices
July 28, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…